Risk of Posterior Capsular Rupture during Phacoemulsification in Patients with the History of Anti-VEGF Intravitreal Injections: Results from the Pan-American Collaborative Retina Study (PACORES) Group

The aim is to assess the risk for capsular rupture during routine phacoemulsification in patients with a history of anti-VEGF injections and other possible risk modifiers such as treatment patterns, type of anti-VEGF agent, and experience of the surgeon, among others. This study reviewed the medical...

Descripción completa

Detalles Bibliográficos
Autores: Velez-Montoya, Raul, Sanchez-Santos, Idaira, Galvan-Chavez, Mauricio, Wu, Lihteh, Fernando Arevalo, J., Berrocal, María H., Alezzandrini, Arturo A., Figueroa, Marta S., Gallego-Pinazo, Roberto, Dolz Marco, Rosa, Martinez-Rubio, Clara, Gonzalez-Salinas, Roberto
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/6801
Acceso en línea:https://hdl.handle.net/20.500.12466/6801
Access Level:acceso abierto
Palabra clave:Risk of Posterior Capsular Rupture
Phacoemulsification
Patients
Anti-VEGF Intravitreal Injections
Pan-American Collaborative Retina Study
32 Ciencias Médicas
3201.09 Oftalmología
Descripción
Sumario:The aim is to assess the risk for capsular rupture during routine phacoemulsification in patients with a history of anti-VEGF injections and other possible risk modifiers such as treatment patterns, type of anti-VEGF agent, and experience of the surgeon, among others. This study reviewed the medical records of 11,129 patients from 7 different hospitals in 5 countries. The study included 939 patients that underwent routine phacoemulsification and had a history of anti-VEGF therapy. We excluded patients with known risk factors for capsular rupture, as well as patients with a history of other retinal procedures. The study extracted data regarding general demographics, the number of previous injections, type of anti-VEGF agent, details of cataract surgery, and anti-VEGF treatment patterns.